Mitraclip insertion to hasten recovery from severe COVID-19 disease

Abstract

The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected 188 countries worldwide with a global death toll of over a million.1 The severe form of the disease is more commonly seen in the elderly and patients with multiple comorbidities and carries a bad prognosis.1, 2 Patients with valvular heart disease are also at an increased risk of adverse outcomes from COVID-19.3 MitraClip (Abbott Vascular, Santa Clara, California) has been approved for functional as well as degenerative mitral regurgitation in the USA.4-8 We describe a case of 67 year old gentleman with severe COVID-19 infection with multiple complications who underwent MitraClip implantation (Abbott Vascular, Santa Clara, California) to treat with refractory pulmonary edema to hasten recovery from this lethal disease.